BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Subscribe To Our Newsletter & Stay Updated
